The first patient has been enrolled in the phase I/II REPARO study, the first international clinical trial evaluating the ophthalmological use of a topical solution of recombinant human Nerve Growth Factor (rhNGF) for the treatment of moderate to severe neurotrophic keratitis (NK).

See the original article here:
Dompé initiates enrollment in rhNGF phase I/II REPARO study for neurotrophic keratitis

Scroll to Top